MA52492A - Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés - Google Patents
Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associésInfo
- Publication number
- MA52492A MA52492A MA052492A MA52492A MA52492A MA 52492 A MA52492 A MA 52492A MA 052492 A MA052492 A MA 052492A MA 52492 A MA52492 A MA 52492A MA 52492 A MA52492 A MA 52492A
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitor compounds
- use processes
- related preparation
- rip1 inhibitor
- rip1
- Prior art date
Links
- 102100021009 Cytochrome b-c1 complex subunit Rieske, mitochondrial Human genes 0.000 title 1
- 101000643956 Homo sapiens Cytochrome b-c1 complex subunit Rieske, mitochondrial Proteins 0.000 title 1
- 101001099199 Homo sapiens RalA-binding protein 1 Proteins 0.000 title 1
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862666452P | 2018-05-03 | 2018-05-03 | |
| PCT/US2019/030473 WO2019213445A1 (fr) | 2018-05-03 | 2019-05-02 | Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA52492A true MA52492A (fr) | 2021-03-10 |
| MA52492B1 MA52492B1 (fr) | 2023-09-27 |
Family
ID=66554488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA52492A MA52492B1 (fr) | 2018-05-03 | 2019-05-02 | Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés |
Country Status (38)
| Country | Link |
|---|---|
| US (3) | US10975064B2 (fr) |
| EP (1) | EP3788045B1 (fr) |
| JP (1) | JP7379467B2 (fr) |
| KR (1) | KR102823195B1 (fr) |
| CN (1) | CN112384510B (fr) |
| AU (1) | AU2019262142B2 (fr) |
| BR (1) | BR112020022423A2 (fr) |
| CA (1) | CA3099018A1 (fr) |
| CL (1) | CL2020002840A1 (fr) |
| CO (1) | CO2020015153A2 (fr) |
| CR (1) | CR20200582A (fr) |
| CY (1) | CY1126152T1 (fr) |
| DK (1) | DK3788045T3 (fr) |
| DO (1) | DOP2020000197A (fr) |
| EA (1) | EA202092581A1 (fr) |
| EC (1) | ECSP20077518A (fr) |
| ES (1) | ES2947446T3 (fr) |
| FI (1) | FI3788045T3 (fr) |
| HR (1) | HRP20230909T1 (fr) |
| HU (1) | HUE062277T2 (fr) |
| IL (1) | IL278416B2 (fr) |
| JO (1) | JOP20200277B1 (fr) |
| LT (1) | LT3788045T (fr) |
| MA (1) | MA52492B1 (fr) |
| MD (1) | MD3788045T2 (fr) |
| MX (1) | MX2020011622A (fr) |
| MY (1) | MY205388A (fr) |
| PE (1) | PE20210414A1 (fr) |
| PH (1) | PH12020551848A1 (fr) |
| PL (1) | PL3788045T3 (fr) |
| PT (1) | PT3788045T (fr) |
| RS (1) | RS64418B1 (fr) |
| SG (1) | SG11202010913PA (fr) |
| SI (1) | SI3788045T1 (fr) |
| SM (1) | SMT202300203T1 (fr) |
| UA (1) | UA128160C2 (fr) |
| WO (1) | WO2019213445A1 (fr) |
| ZA (1) | ZA202007487B (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3788045T3 (pl) * | 2018-05-03 | 2023-10-09 | Rigel Pharmaceuticals, Inc. | Związki hamujące rip1 oraz sposoby ich wytwarzania i wykorzystania |
| SI3788044T1 (sl) | 2018-05-03 | 2023-12-29 | Rigel Pharmaceuticals, Inc. | Spojine, ki zavirajo RIP1 in postopki za njihovo izdelavo in uporabo |
| BR112021009610A2 (pt) | 2018-11-20 | 2021-08-10 | Sironax Ltd | composto, composição farmacêutica, uso de um composto ou composição, e, método de inibir necrose, ferroptose, rip1 humana ou indicações relacionadas |
| US11718612B2 (en) | 2019-09-06 | 2023-08-08 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase I for the treatment of disease |
| ES3043457T3 (en) * | 2019-09-06 | 2025-11-25 | Rigel Pharmaceuticals Inc | Rip1 inhibitory compounds and methods for making and using the same |
| AU2020341708B2 (en) | 2019-09-06 | 2024-01-04 | Rigel Pharmaceuticals, Inc. | RIP1 inhibitory compounds and methods for making and using the same |
| IL291665B2 (en) | 2019-09-27 | 2025-07-01 | Univ Texas | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
| SMT202600151T1 (it) * | 2019-11-07 | 2026-05-12 | Rigel Pharmaceuticals Inc | Composti eterociclici inibitori di rip1 |
| AU2020391425A1 (en) * | 2019-11-26 | 2022-06-16 | Board Of Regents, The University Of Texas System | Inhibitors of Receptor Interacting Protein Kinase 1 for the treatment of disease |
| AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
| TWI824259B (zh) | 2020-07-01 | 2023-12-01 | 美商雷傑製藥公司 | Rip1k抑制劑 |
| EP4200281A4 (fr) * | 2020-08-18 | 2024-09-25 | Hutchison Medipharma Limited | Composés de pyrimidinone et leurs utilisations |
| TW202300490A (zh) | 2021-03-11 | 2023-01-01 | 美商雷傑製藥公司 | 雜環rip1激酶抑制劑 |
| WO2022237890A1 (fr) * | 2021-05-14 | 2022-11-17 | 中国医药研究开发中心有限公司 | Composé à cycle fusionné du type azépine et son utilisation pharmaceutique |
| CN115894489A (zh) * | 2021-09-22 | 2023-04-04 | 中国药科大学 | 一种受体相互作用蛋白激酶1的抑制剂及其制备方法、应用 |
| US20240425524A1 (en) * | 2021-10-27 | 2024-12-26 | Merck Sharp & Dohme Llc | Spirotricycle ripk1 inhibitors and methods of uses thereof |
| KR20230100646A (ko) * | 2021-12-24 | 2023-07-05 | 제일약품주식회사 | Ripk1 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
| JP2025510009A (ja) * | 2022-02-28 | 2025-04-14 | シロナックス リミテッド． | Ｒｉｐ１調節物質、その調製、及び使用 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5087240A (en) | 1983-08-18 | 1992-02-11 | Drug Delivery Systems Inc. | Transdermal drug patch with conductive fibers |
| US4921475A (en) | 1983-08-18 | 1990-05-01 | Drug Delivery Systems Inc. | Transdermal drug patch with microtubes |
| US4738851A (en) | 1985-09-27 | 1988-04-19 | University Of Iowa Research Foundation, Inc. | Controlled release ophthalmic gel formulation |
| US5163899A (en) | 1987-03-20 | 1992-11-17 | Drug Delivery Systems Inc. | Transdermal drug delivery system |
| US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
| GB8804164D0 (en) | 1988-02-23 | 1988-03-23 | Tucker J M | Bandage for administering physiologically active compound |
| US4882150A (en) | 1988-06-03 | 1989-11-21 | Kaufman Herbert E | Drug delivery system |
| US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
| US5088977A (en) | 1988-12-21 | 1992-02-18 | Drug Delivery Systems Inc. | Electrical transdermal drug applicator with counteractor and method of drug delivery |
| US5521222A (en) | 1989-09-28 | 1996-05-28 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
| CA2031376A1 (fr) | 1989-12-04 | 1991-06-05 | Bahram Farhadieh | Dispositif transdermique monocouche pour l'administration de medicaments |
| US5077033A (en) | 1990-08-07 | 1991-12-31 | Mediventures Inc. | Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide |
| DK0495421T3 (da) | 1991-01-15 | 1996-12-09 | Alcon Lab Inc | Anvendelse af carragenaner i topiske ophthalmiske sammensætninger |
| US5352456A (en) | 1991-10-10 | 1994-10-04 | Cygnus Therapeutic Systems | Device for administering drug transdermally which provides an initial pulse of drug |
| CA2123809A1 (fr) | 1991-12-18 | 1993-06-24 | Debra L. Wilfong | Pellicule d'etancheite multicouche |
| ATE132381T1 (de) | 1992-01-29 | 1996-01-15 | Voelkl Franz Ski | Ballspielschläger, insbesondere tennisschläger |
| IL114193A (en) | 1994-06-20 | 2000-02-29 | Teva Pharma | Ophthalmic pharmaceutical compositions based on sodium alginate |
| ES2094688B1 (es) | 1994-08-08 | 1997-08-01 | Cusi Lab | Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. |
| IT1283911B1 (it) | 1996-02-05 | 1998-05-07 | Farmigea Spa | Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo |
| US5800807A (en) | 1997-01-29 | 1998-09-01 | Bausch & Lomb Incorporated | Ophthalmic compositions including glycerin and propylene glycol |
| US6261547B1 (en) | 1998-04-07 | 2001-07-17 | Alcon Manufacturing, Ltd. | Gelling ophthalmic compositions containing xanthan gum |
| US6197934B1 (en) | 1998-05-22 | 2001-03-06 | Collagenesis, Inc. | Compound delivery using rapidly dissolving collagen film |
| CA2696349A1 (fr) | 2007-08-15 | 2009-02-19 | President And Fellows Of Harvard College | Inhibiteurs heterocycliques de la necroptose |
| TWI648274B (zh) * | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 （二） |
| WO2014145022A1 (fr) | 2013-03-15 | 2014-09-18 | President And Fellows Of Harvard College | Inhibiteurs hybrides de la nécroptose |
| RU2017109122A (ru) * | 2014-08-21 | 2018-09-21 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Способы лечения с использованием гетероциклических амидов в качестве ингибиторов киназы |
| EP3256467A1 (fr) | 2015-02-13 | 2017-12-20 | GlaxoSmithKline Intellectual Property Management Limited | Formes cristallines de (s)-5-benzyl-n-(5-méthyl-4-oxo-2,3,4,5-tétrahydrobenzo[b][1,4]oxazépine-3-yl)-4h-1,2,4-triazole-3-carboxamide |
| RU2716136C2 (ru) * | 2015-07-02 | 2020-03-06 | Ф. Хоффманн-Ля Рош Аг | Бициклические лактамы и способы их применения |
| WO2017064217A1 (fr) | 2015-10-13 | 2017-04-20 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Dérivés de sibiriline destinés à être utilisés dans la prévention et/ou le traitement des troubles associés à la nécroptose cellulaire |
| WO2017069279A1 (fr) | 2015-10-23 | 2017-04-27 | 武田薬品工業株式会社 | Composé hétérocyclique |
| US10961258B2 (en) | 2015-12-21 | 2021-03-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| US9815850B2 (en) | 2016-02-05 | 2017-11-14 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| JP7349359B2 (ja) | 2016-10-17 | 2023-09-22 | エフ． ホフマン－ラ ロシュ アーゲー | 二環式ピリドンラクタム及びその使用方法。 |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| EP3585782A1 (fr) | 2017-02-27 | 2020-01-01 | GlaxoSmithKline Intellectual Property Development Limited | Amides hétérocycliques en tant qu'inhibiteurs de kinase |
| SI3788044T1 (sl) | 2018-05-03 | 2023-12-29 | Rigel Pharmaceuticals, Inc. | Spojine, ki zavirajo RIP1 in postopki za njihovo izdelavo in uporabo |
| PL3788045T3 (pl) | 2018-05-03 | 2023-10-09 | Rigel Pharmaceuticals, Inc. | Związki hamujące rip1 oraz sposoby ich wytwarzania i wykorzystania |
| WO2020001420A1 (fr) | 2018-06-26 | 2020-01-02 | 中国科学院上海有机化学研究所 | Inhibiteur de nécrose cellulaire, son procédé de préparation et son utilisation |
| JP7045526B2 (ja) | 2018-11-02 | 2022-03-31 | 中国科学院上海薬物研究所 | Ｒｉｐ１キナーゼを阻害する複素環状アミド及びその使用 |
| ES3043457T3 (en) | 2019-09-06 | 2025-11-25 | Rigel Pharmaceuticals Inc | Rip1 inhibitory compounds and methods for making and using the same |
| AU2020341708B2 (en) | 2019-09-06 | 2024-01-04 | Rigel Pharmaceuticals, Inc. | RIP1 inhibitory compounds and methods for making and using the same |
| SMT202600151T1 (it) * | 2019-11-07 | 2026-05-12 | Rigel Pharmaceuticals Inc | Composti eterociclici inibitori di rip1 |
| AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
-
2019
- 2019-05-02 PL PL19724662.2T patent/PL3788045T3/pl unknown
- 2019-05-02 BR BR112020022423-5A patent/BR112020022423A2/pt unknown
- 2019-05-02 MA MA52492A patent/MA52492B1/fr unknown
- 2019-05-02 DK DK19724662.2T patent/DK3788045T3/da active
- 2019-05-02 LT LTEPPCT/US2019/030473T patent/LT3788045T/lt unknown
- 2019-05-02 AU AU2019262142A patent/AU2019262142B2/en active Active
- 2019-05-02 RS RS20230648A patent/RS64418B1/sr unknown
- 2019-05-02 PT PT197246622T patent/PT3788045T/pt unknown
- 2019-05-02 PE PE2020001796A patent/PE20210414A1/es unknown
- 2019-05-02 FI FIEP19724662.2T patent/FI3788045T3/fi active
- 2019-05-02 MX MX2020011622A patent/MX2020011622A/es unknown
- 2019-05-02 SI SI201930550T patent/SI3788045T1/sl unknown
- 2019-05-02 HU HUE19724662A patent/HUE062277T2/hu unknown
- 2019-05-02 WO PCT/US2019/030473 patent/WO2019213445A1/fr not_active Ceased
- 2019-05-02 JP JP2021510283A patent/JP7379467B2/ja active Active
- 2019-05-02 US US16/402,103 patent/US10975064B2/en active Active
- 2019-05-02 CN CN201980045150.5A patent/CN112384510B/zh active Active
- 2019-05-02 CA CA3099018A patent/CA3099018A1/fr active Pending
- 2019-05-02 KR KR1020207034544A patent/KR102823195B1/ko active Active
- 2019-05-02 HR HRP20230909TT patent/HRP20230909T1/hr unknown
- 2019-05-02 CR CR20200582A patent/CR20200582A/es unknown
- 2019-05-02 EP EP19724662.2A patent/EP3788045B1/fr active Active
- 2019-05-02 MD MDE20210214T patent/MD3788045T2/ro unknown
- 2019-05-02 IL IL278416A patent/IL278416B2/en unknown
- 2019-05-02 ES ES19724662T patent/ES2947446T3/es active Active
- 2019-05-02 MY MYPI2020005729A patent/MY205388A/en unknown
- 2019-05-02 EA EA202092581A patent/EA202092581A1/ru unknown
- 2019-05-02 UA UAA202007282A patent/UA128160C2/uk unknown
- 2019-05-02 SG SG11202010913PA patent/SG11202010913PA/en unknown
- 2019-05-02 SM SM20230203T patent/SMT202300203T1/it unknown
-
2020
- 2020-11-02 CL CL2020002840A patent/CL2020002840A1/es unknown
- 2020-11-02 DO DO2020000197A patent/DOP2020000197A/es unknown
- 2020-11-03 JO JOJO/P/2020/0277A patent/JOP20200277B1/ar active
- 2020-11-03 PH PH12020551848A patent/PH12020551848A1/en unknown
- 2020-12-01 ZA ZA2020/07487A patent/ZA202007487B/en unknown
- 2020-12-01 EC ECSENADI202077518A patent/ECSP20077518A/es unknown
- 2020-12-01 CO CONC2020/0015153A patent/CO2020015153A2/es unknown
-
2021
- 2021-03-23 US US17/210,261 patent/US11919890B2/en active Active
-
2023
- 2023-07-25 CY CY20231100349T patent/CY1126152T1/el unknown
-
2024
- 2024-02-05 US US18/432,727 patent/US20240217958A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52488A (fr) | Composés inhibiteurs de rip1 et leurs procédés de fabrication et d'utilisation | |
| MA56032A (fr) | Composés, compositions et procédés d'utilisation | |
| EP3768267A4 (fr) | Composés inhibiteurs de kinase, compositions et procédés d'utilisation | |
| MA50045A (fr) | Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci | |
| EP3923935A4 (fr) | Composés, compositions et procédés | |
| EP3713560A4 (fr) | Composés bêta-hydroxybutyrate non racémiques et compositions enrichies en l'énantiomère r, et leurs procédés d'utilisation | |
| EP3675847A4 (fr) | Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci | |
| EP3781563A4 (fr) | Inhibiteurs d'hpk1, procédé de préparation et utilisation associés | |
| HUE062277T2 (hu) | RIP1 inhibitorvegyületek, valamint ezek elõállítása és alkalmazása | |
| EP3761980A4 (fr) | Composés d'acides aminés et leurs procédés d'utilisation | |
| MA48942A (fr) | Composés thérapeutiques, compositions et procédés d'utilisation associés | |
| EP3370715A4 (fr) | Composés chimères de ciblage de protéolyse et procédés de préparation et d'utilisation de ceux-ci | |
| EP3645049A4 (fr) | Anticorps multispécifiques et procédés de préparation et d'utilisation associés | |
| MA54148A (fr) | Mélanges et compositions comprenant de la 5-fluoro-4-imino-3-méthyl-1-tosyl-3,4-dihydropyrimidin-2-one et leurs procédés d'utilisation | |
| MA54959A (fr) | Composés, compositions et procédés | |
| MA49560A (fr) | Composés cétoniques bicycliques et leurs procédés d'utilisation | |
| EP3964518C0 (fr) | Inhibiteur de cd73, son procédé de préparation et son utilisation | |
| EP3790552A4 (fr) | Compositions de combinaison comprenant des composés de bisfluoroalkyle-1,4-benzodiazépinone et leurs procédés d'utilisation | |
| MA55532A (fr) | Composés de neuréguline-4 et procédés d'utilisation | |
| EP3619193A4 (fr) | Composés amino-aryl-benzamide et leurs procédés d'utilisation | |
| EP3920977A4 (fr) | Procédés améliorés d'angiographie | |
| EP3853352A4 (fr) | Plaque de puits fonctionnalisée, procédés de préparation et d'utilisation de celle-ci | |
| EP3911355A4 (fr) | Lubricines recombinantes, compositions et procédés d'utilisation de celles-ci | |
| EP3687551A4 (fr) | Composés de porphyrine fluorosubstitué, compositions les comprenant et procédés de préparation et d'utilisation associés | |
| EP3773773A4 (fr) | Compositions d'encre à base de soie et procédés de préparation et d'utilisation de celles-ci |